Table 1.
Comparison of demographic characteristics between two groups.
| Group A | Group B | p value | |
|---|---|---|---|
| (n = 115) (%) | (n = 100) (%) | ||
| Sex, male | 73 (63.5%) | 61 (61.0%) | 0.708 |
| Age (year) | 61.43 ± 10.66 | 59.77 ± 10.74 | 0.259 |
| BMI (kg/m2) | 22.87 ± 3.185 | 23.33 ± 2.91 | 0.274 |
| Smoking | 46 (40.0%) | 48 (48.0%) | 0.238 |
| Alcohol consumption | 44 (34.8%) | 44 (44.0%) | 0.393 |
| Comorbidity | |||
| Hypertension | 26 (22.6%) | 23 (23.0%) | 0.946 |
| Diabetes | 16 (13.9%) | 8 (8.0%) | 0.170 |
| Coronary disease | 14 (12.2%) | 11 (11.0%) | 0.789 |
| Pneumonia | 6 (5.2%) | 9 (9.0%) | 0.278 |
| Hepatitis | 3 (2.6%) | 8 (8.0%) | 0.118 |
| ASA score | 0.668 | ||
| I | 37 (32.2%) | 38 (38.0%) | |
| II | 51 (44.3%) | 41 (41.0%) | |
| III | 27 (23.5%) | 21 (21.0%) | |
| cTNM stage | 0.475 | ||
| I | 5 (4.3%) | 8 (8.0%) | |
| II | 37 (32.2%) | 28 (28.0%) | |
| III | 73 (63.5%) | 64 (64.0%) | |
| ypTNM stage | 0.917 | ||
| 0 | 1 (0.9%) | 2 (2.0%) | |
| I | 7 (6.1%) | 10 (10.0%) | |
| II | 11 (9.6%) | 12 (12.0%) | |
| III | 13 (11.3%) | 20 (20.0%) | |
| Neoadjuvant radiotherapy | 22 (19.1%) | 28 (28.0%) | 0.125 |
| Neoadjuvant chemotherapy | 32 (27.9%) | 36 (36.0%) | 0.199 |
| Tumor location (cm) | 5.97 ± 2.12 | 5.52 ± 2.12 | 0.127 |
| Albumin(g/L) | 37.99 ± 4.03 | 37.79 ± 3.83 | 0.583 |
| Serum creatinine(μmol/L) | 70.97 ± 17.44 | 70.59 ± 11.14 | 0.854 |
| Stoma location, right | 46 (40.0%) | 50 (50.0%) | 0.141 |
| Distance between stoma and ileocecal part (cm) | 35.33 ± 9.36 | 33.07 ± 11.38 | 0.245 |
BMI, body mass index; ASA, American Society of Anesthesiologists; cTNM, clinical tumor node metastasis; ypTNM, neoadjuvant pathological tumor node metastasis.